MedTrace Logo

Psilocybin for Prolonged Grief Disorder

NCT06724289 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-03-03

No results posted yet for this study

Summary

The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).

Conditions

  • Prolonged Grief Disorder

Interventions

DRUG

Psilocybin 25 mg

25 mg psilocybin administered to each participant in single arm, open-label trial

DIAGNOSTIC_TEST

Functional Magnetic Resonance Imaging (fMRI)

There are two "fMRIs" (functional magnetic resonance imaging) that take place 1-14 days before and 1-14 days after psilocybin administration.

Sponsors & Collaborators

  • Tiny Blue Dot Foundation

    collaborator OTHER

  • Texas Tech University

    collaborator OTHER

  • University of Virginia

    lead OTHER

Principal Investigators

  • Jennifer K Penberthy, PhD · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06724289 on ClinicalTrials.gov